Firestein received his A.B. in chemistry from Harvard College in Cambridge, MA, in 1976 and his M.D. from Johns Hopkins University School of Medicine in Baltimore, MD, in 1980. He completed his residency at the UCLA School of Medicine, followed by two fellowships, one in molecular biology at the La Jolla Cancer Research Institute in La Jolla, CA, and one in rheumatology at the University of California San Diego. He is board-certified in internal medicine and rheumatology. Firestein joined the faculty at UC San Diego School of Medicine as Assistant Professor of Medicine in 1988. Four years later, he was recruited by Gensia, Inc. to be Director of Immunology where he supervised drug discovery efforts focusing on the potential role of purines in inflammation. In 1996 he was elected to the American Society for Clinical Investigation. That same year, he returned to UC San Diego where he served as Chief of the Division of Rheumatology, Allergy and Immunology from 1998 until 2010. In 2008, he became the Dean of Translational Medicine. In 2010, he became Associate Vice Chancellor of Translational Medicine and Director of the newly established ACTRI, which is funded in part through the NIH Clinical and Translational Science Awards Program. In 2020, the ACTRI was awarded its third consecutive successful NCATS CTSA U54 Award under Firestein's leadership, with an additional dedicated to the advancement of clinical and translational science. He is the co-founder of Ignyta, Inc., a biotech company that went public in 2015 and was acquired by Roche in 2018. Its lead drug entrectinib was approved by the US Food and Drug Administration for certain cancers. He is the co-creator of the University of California CTSA consortium called UC BRAID and served as its chairperson from 2013-2015. During his career, Firestein has served as the Principal Investigator on grants totaling more than $150 M in research funding, including numerous NIH and commercial-sponsored research grants and clinical trials. Firestein is the Editor-in-Chief of Firestein and Kelley’s Textbook of Rheumatology, with the 11th edition forthcoming. He has written over 350 articles and book chapters, and is past Deputy Editor of Arthritis & Rheumatism.
Service
Dr. Firestein is past chairperson of the FDA Arthritis Advisory Committee and has served on the Board of Directors of the American College of Rheumatology, ACR Research and Education Foundation, as chairperson of the ACR Committee on Journal Publications, on the ACR Committee on Research, on the Arthritis Foundation Research Committee, on the Board of Directors for the Veteran's Medical Research Foundation, and on the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases Advisory Council.
Research and honors
Dr. Firestein's research focuses on the pathogenesis of rheumatoid arthritis, and his work contributed to the development of anti-cytokine therapy and signal transduction inhibitors that are now approved for use in many countries. More recently, he mapped the epigenome landscape of rheumatoid arthritis and used novel informatics tools to identify pathogenic pathways and novel therapeutic targets. Dr. Firestein was also the first to use percutaneous synovial biopsies to evaluate drug mechanism of action in arthritis and demonstrated that somatic mutation could increase joint damage in rheumatoid arthritis. His Google Scholar H index is 98 with approximately 40,000 citations. Firestein has received the Carol-Nachman Prize for Rheumatology, the Arthritis Foundation Lee C. Howley Sr. Prize for Arthritis Research, the ACR Distinguished Investigator Award, and the Jane Wyman Humanitarian Award. He has been elected to the American Society for Clinical Investigation and the Association of American Physicians. Dr. Firestein received a Doctor of Science from University of Glasgow in June 2019.
Personal
He is married to Linda Lyons Firestein, M.D., and they have a son and a daughter. Dr. Firestein enjoys surfing and playing bluegrass music on the banjo.
